Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Cut to Market Perform at Sanford C. Bernstein

Posted by Brenda Bartman on Oct 31st, 2026

Sanford C. Bernstein cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from an outperform rating to a market perform rating in a research note issued to investors on Friday, MarketBeat Ratings reports. They currently have $199.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $376.00.

Other equities research analysts also recently issued research reports about the company. Oppenheimer cut their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Bank of America reissued a “buy” rating and issued a $287.00 target price (down from $460.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 30th. Finally, Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $317.95.

Check Out Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $165.00 on Friday. The stock has a 50 day moving average price of $236.49 and a 200 day moving average price of $286.19. Alnylam Pharmaceuticals has a 52 week low of $163.30 and a 52 week high of $479.79. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a market capitalization of $22.08 billion, a PE ratio of 8.57 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 246.94% and a net margin of 52.85%. The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $2.90 earnings per share. Analysts predict that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Rakuten Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 13.0% in the 3rd quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock valued at $5,155,000 after buying an additional 2,328 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $527,000. GraniteShares Advisors LLC increased its position in Alnylam Pharmaceuticals by 12.7% during the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 205 shares during the period. Traynor Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 22.6% during the third quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 2,360 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $18,226,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.